EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - EyePoint, Inc. is focused on developing innovative therapeutics for serious retinal diseases and will present at the J.P. Morgan Healthcare Conference on January 13, 2026 [1] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with serious retinal diseases [3] - The company's lead product candidate, DURAVYU, is an investigational sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E technology [3] - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration, with topline data expected in mid-2026, and first patient dosing in diabetic macular edema trials anticipated in Q1 2026 [3] Product and Development - Vorolanib is exclusively licensed to EyePoint for the localized treatment of ophthalmic diseases outside of specific regions in Asia [5] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901, but it remains an investigational product and has not yet received FDA approval [5] Commitment to Community - The company aims to partner with the retina community to enhance patient lives while creating long-term value, having developed four approved drugs over three decades and treated tens of thousands of eyes [4]